R
Robert A. Rosenheck
Researcher at Yale University
Publications - 993
Citations - 58354
Robert A. Rosenheck is an academic researcher from Yale University. The author has contributed to research in topics: Mental health & Veterans Affairs. The author has an hindex of 114, co-authored 963 publications receiving 54357 citations. Previous affiliations of Robert A. Rosenheck include Eastern Virginia Medical School & The Feinstein Institute for Medical Research.
Papers
More filters
Journal ArticleDOI
Time-Limited Assertive Community Treatment for Homeless Persons With Severe Mental Illness
TL;DR: Homeless clients who have severe mental illness can be selectively discharged or transferred from ACT to other services without subsequent loss of gains in mental health status, substance abuse, housing, or employment.
Journal ArticleDOI
Effects of ethnicity on psychotropic medications adherence.
TL;DR: Depressive symptoms were associated with lower adherence and more years of past treatment with higher adherence among Caucasians, and monolingual-Hispanics and African–Americans had lower medication adherence rates than whites.
Journal ArticleDOI
Long-term course of treatment-seeking Vietnam veterans with posttraumatic stress disorder: mortality, clinical condition, and life satisfaction.
TL;DR: Results indicate that the majority of the veteran sample had experienced some improvement in their ability to cope with their chronic illness, decreasing their use of violence and substance abuse but still were experiencing high levels of symptomatology.
Journal ArticleDOI
Smoking among chronically homeless adults: prevalence and correlates.
Jack Tsai,Robert A. Rosenheck +1 more
TL;DR: Having a diagnosis of posttraumatic stress disorder and reducing alcohol use predicted quitting or limiting smoking, and change in alcohol and drug use was associated with change in smoking status in the same direction.
Journal ArticleDOI
Impact of Clozapine on Negative Symptoms and on the Deficit Syndrome in Refractory Schizophrenia
Robert A. Rosenheck,Lawrence A. Dunn,Michael Peszke,Joyce A. Cramer,Weichun Xu,Jonathan Thomas,Dennis S. Charney +6 more
TL;DR: The greater effectiveness of clozapine as compared to conventional medications in refractory schizophrenia is not specific to either negative clinical symptoms or clinical subtypes defined by prominent negative symptoms or evidence of the deficit syndrome.